Telomir announces peer-reviewed preclinical study showing drug reduced liver injury in disease model

Filed May 20, 2026 · Period ending May 20, 2026 · ~1 min read

Key Changes

• medium

  Telomir-1 reduced oxidative stress, liver copper buildup, and injury markers in a zebrafish model of Wilson's disease, a genetic disorder causing toxic copper accumulation in organs.

  Press Release, May 20, 2026 view on EDGAR →
• medium

  Study published in peer-reviewed journal Advances in Redox Research, providing independent scientific validation of the company's lead drug candidate in preclinical testing.

  Press Release, May 20, 2026 view on EDGAR →
• medium

  Drug improved survival outcomes and locomotor performance in the animal model, suggesting potential therapeutic benefit beyond just biochemical markers.

  Press Release, May 20, 2026 view on EDGAR →